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Background 
• Mosquito-borne viral disease characterized by acute 
onset of fever and severe polyarthralgia 
• Often occurs as large outbreaks with high attack rates  
• Outbreaks have occurred in countries in Africa, Asia, 
Europe, and the Indian and Pacific Oceans 
• In late 2013, first local transmission in the Americas was 
reported on islands in the Caribbean 
 
Chikungunya virus 
• Single-stranded RNA virus 
• Genus Alphavirus;  Family Togaviridae 
 
Mosquito vectors 
 
• Aedes aegypti and Aedes albopictus are the primary 
vectors (above) 
• Both are aggressive daytime biting mosquitoes 
 
Animal hosts 
• Humans are the primary host of chikungunya virus 
during epidemic periods 
 
Clinical findings 
• Majority of infected people become symptomatic 
• Incubation period usually 3–7 days (range 1–12 days) 
• Patients typically present with acute onset of fever and 
polyarthralgia 
• Joint symptoms usually symmetric and often occur in 
hands and feet; they can be severe and debilitating 
• Other symptoms may include headache, myalgia, 
arthritis, conjunctivitis, nausea/vomiting, or 
maculopapular rash  
• Clinical laboratory findings can include lymphopenia, 
thrombocytopenia, elevated creatinine, and elevated 
hepatic transaminases  
 
Laboratory testing 
• Evaluate serum or plasma by: 
o Viral culture to detect virus in first 3 days of illness 
o RT-PCR to detect viral RNA in first 8 days of illness 
o Serology to detect IgM, IgG, and neutralizing antibodies 
that develop toward the end of the first week of illness 
• Chikungunya testing is performed at CDC, several state 
health departments, and one commercial laboratory 
• Contact your state health department for more information 
and to facilitate testing 
 
Clinical course and outcomes 
• Acute symptoms typically resolve within 7–10 days 
• Rare complications include uveitis, retinitis, myocarditis, 
hepatitis, nephritis, bullous skin lesions, hemorrhage, 
meningoencephalitis, myelitis, Guillain-Barré syndrome, 
and cranial nerve palsies 
• Persons at risk for severe disease include neonates exposed 
intrapartum, older adults (e.g., > 65 years), and persons 
with underlying medical conditions (e.g., hypertension, 
diabetes, or cardiovascular disease) 
• Some patients might have relapse of rheumatologic 
symptoms (e.g., polyarthralgia, polyarthritis, tenosynovitis) 
in the months following acute illness 
• Studies report variable proportions of patients with 
persistent joint pains for months to years 
• Mortality is rare and occurs mostly in older adults 
 
Treatment 
• No specific antiviral therapy 
• Supportive care with rest and fluids 
• Non-steroidal anti-inflammatory drugs (NSAIDs) to relieve 
acute pain and fever 
• Persistent joint pain may benefit from use of NSAIDs, 
corticosteroids, or physiotherapy 
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Distinguish dengue from chikungunya 
• Dengue and chikungunya viruses are transmitted by the 
same mosquitoes and have similar clinical features 
• The two viruses can circulate in the same area and can 
cause occasional co-infections in the same patient 
• Chikungunya virus infection more likely to cause high 
fever, severe arthralgia, arthritis, rash, and lymphopenia 
• Dengue virus infection more likely to cause neutropenia, 
thrombocytopenia, hemorrhage, shock, and deaths   
• Important to rule out dengue virus infection because 
proper clinical management can improve outcome 
 
Differential diagnosis 
• Varies based on place of residence, travel history, and 
exposures 
• In addition to dengue, other considerations include 
leptospirosis, malaria, rickettsia, group A streptococcus, 
rubella, measles, parvovirus, enteroviruses, adenovirus, 
other alphavirus infections (e.g., Mayaro, Ross River, 
Barmah Forest, O’nyong-nyong, and Sindbis viruses), post-
infections arthritis, and rheumatologic conditions 
 
 
Countries with reported local transmission of 
chikungunya virus (as of February 2014) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surveillance and reporting 
• Chikungunya virus infection should be considered in 
patients with acute onset of fever and polyarthralgia, 
especially travelers who recently returned from areas 
with known virus transmission 
• Healthcare providers are encouraged to report suspected 
chikungunya cases to their state or local health 
department to facilitate diagnosis and mitigate the risk of 
local transmission 
• Health departments should perform surveillance for 
chikungunya cases in returning travelers and be aware of 
the risk of possible local transmission in areas where 
Aedes species mosquitoes are active 
• State health departments are encouraged to report 
confirmed chikungunya virus infections to CDC 
 
Prevention and control 
• No vaccine or medication is available to prevent 
chikungunya virus infection or disease 
• Reduce mosquito exposure 
o Use air conditioning or window/door screens 
o Use mosquito repellents on exposed skin 
o Wear long-sleeved shirts and long pants 
o Wear permethrin-treated clothing 
o Empty standing water from outdoor containers 
o Support local vector control programs 
• People infected with chikungunya or dengue virus should 
be protected from further mosquito exposure during the 
first week of illness to reduce the risk of local transmission 
• People at increased risk for severe disease should 
consider not traveling to areas with ongoing 
chikungunya outbreaks 
 
FOR MORE INFORMATION VISIT: http://www.cdc.gov/chikungunya/ 
